Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
NCT ID: NCT00376090
Last Updated: 2017-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2005-07-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I Vaccine
MVA-CMDR
10\^7 PFU IM, 1.0 mL
Group I Placebo
Placebo
1.0 mL IM
Group II Vaccine
MVA-CMDR
10\^6 PFU ID, 0.1 mL
Group II Placebo
Placebo
0.1 mL ID
Group III Vaccine
MVA-CMDR
10\^8 PFU IM, 1.0 mL
Group III Placebo
Placebo
1.0 mL IM
Group IV Vaccine
MVA-CMDR
10\^7 PFD ID, 0.1 mL
Group IV Placebo
Placebo
0.1 mL ID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MVA-CMDR
10\^7 PFU IM, 1.0 mL
Placebo
1.0 mL IM
MVA-CMDR
10\^6 PFU ID, 0.1 mL
Placebo
0.1 mL ID
MVA-CMDR
10\^8 PFU IM, 1.0 mL
MVA-CMDR
10\^7 PFD ID, 0.1 mL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Low risk for HIV infection
* 18 to 40 years at the time of enrollment and vaccinia naive
* Good health
* Availability for 12 months of participation.
* Successful completion of the Test of Understanding
* Able and willing to give informed consent.
* HEMATOCRIT: WOMEN: 35 %-45 %; MEN 36 % - 49 %
* White cell count: 3,000 - 11,000 cells/mm3
* Platelets: 125,000 - 450,000 per mm3
* Normal cardiac enzyme level at second Screening Visit
* Urinalysis (UA) for protein and blood: negative or trace.
* Normal liver function tests to include ALT/AST, alkaline phosphatase, GGT (\< 1.25x institutional upper limits of normal) and CPK (\< 480) and creatinine (\< 1.25 mg/dL)
* Negative serology for HIV infection
* Any female volunteer must have a negative serum or urine pregnancy test at the screening visit as well as immediately prior to each vaccine/placebo vaccination, as well as verbal assurance that adequate birth control measures have been followed for 60 days prior to the first vaccine/placebo vaccination and will continue to be followed for at least 3months after the final vaccine/placebo vaccination. This means using any of the following methods: Birth control drugs that prevent pregnancy given by pills, shots or placed under the skin, Male or female condoms with or without a cream or gel that kills sperm, diaphragm or cervical cap with a cream or gel that kills sperm, or Abstinence
Exclusion Criteria
A woman who:
* Is pregnant.
* Is breast-feeding.
Anyone who:
* Is U.S. military personnel.
* Acknowledges engaging in highest-risk behavior within six months of study entry
* Has active tuberculosis or other systemic infectious process by review of systems and physical examination.
* Has history of or known cardiac disease including any of the following: prior myocardial infarction (heart attack), angina pectoris, congestive heart failure, conduction disturbances, repolarization (ST segment or T wave) abnormalities, serious cardiac arrhythmias (ventricular tachycardia or ventricular fibrillation), cardiomyopathy, pericarditis, stroke or transient ischemic attack, chest pain or shortness of breath with activity (e.g. climbing stairs), valvular heart disease including mitral valve prolapse, or other heart conditions under the care of a doctor.
* Has ECG on Screening Visit 2 with clinical significant findings, or features that would interfere with the assessment of myo/pericarditis (as determined by the contract ECG Lab) including any of the following: conduction disturbance (atrioventricular or intraventricular condition, left or right bundle branch block, AB block of any degree or QTc prolongation), repolarization (ST segment or T wave) abnormality, significant atrial or ventricular arrhythmia, frequent atrial or ventricular ectopy (e.g. frequent premature atrial contractions, 2 premature ventricular contractions in a row), ST elevation consistent with ischemia, or evidence of past or evolving myocardial infarction
* Has history of seizure disorder, immunodeficiency, chronic illness, autoimmune disease, diabetes mellitus active malignancy or use of immunosuppressive medications.
* Has evidence of psychiatric, medical and/or substance abuse problems during the past six months that the investigator believes would adversely affect the volunteer's ability to participate in the trial.
* Has occupational or other responsibilities that would prevent completion of participation in the study.
* Has received any live attenuated vaccine within 60 days of study entry.
* Has used experimental therapeutic agents within 30 days of study entry.
* Has received blood products or immunoglobulins in the past three months.
* Has history of anaphylaxis or other serious adverse reactions to vaccines.
* Has previously received an HIV vaccine or an MVA or vaccinia vaccine.
* Has chronic or active Hepatitis B or Hepatitis C virus infection or active syphilis (positive RPR and FTA).
* Has had an immediate type hypersensitivity reaction to eggs, egg products or neomycin/streptomycin (used to prepare MVA vaccine).
* Is a study site employee.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U.S. Army Medical Research and Development Command
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary Marovich, MD, DTM&H
Role: PRINCIPAL_INVESTIGATOR
US Military HIV Research Program
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
US Military HIV Research Program
Rockville, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-12403
Identifier Type: OTHER
Identifier Source: secondary_id
WRAIR 1143
Identifier Type: OTHER
Identifier Source: secondary_id
RV 158
Identifier Type: -
Identifier Source: org_study_id